Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Akari Therapeutics PLC AKTX

Healthcare  —  Biotechnology
9.76 (0.30) (2.98%) as of 25 Sep
Market cap
$17.6M
P/E
0.0×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Akari Therapeutics PLC (AKTX) Business Profile

Updated before January 2025

Company Overview

Akari Therapeutics PLC (NASDAQ: AKTX) is a biopharmaceutical company focused on the development of innovative treatments for rare and orphan diseases. Founded in 2008, the company is headquartered in London, United Kingdom, with additional operations in the United States. Akari Therapeutics specializes in leveraging its proprietary pipeline of therapeutic candidates to address unmet medical needs in areas such as autoimmune and inflammatory diseases. The company is led by a team of experienced executives and scientists, including its CEO, Rachelle Jacques, who brings extensive expertise in the pharmaceutical and biotechnology sectors.

Core Business Segments

Akari Therapeutics operates primarily in the biopharmaceutical sector, with a focus on developing treatments for rare diseases. The company’s core business segments include:

1. Complement Inhibition Therapies

Akari’s flagship product candidate, nomacopan, is a small recombinant protein that acts as a dual inhibitor of complement C5 and leukotriene B4 (LTB4). This dual mechanism of action positions nomacopan as a potential treatment for a range of inflammatory and autoimmune conditions, including:

  • Paroxysmal Nocturnal Hemoglobinuria (PNH): A rare blood disorder characterized by the destruction of red blood cells.
  • Bullous Pemphigoid (BP): A chronic autoimmune skin condition.
  • Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA): A life-threatening complication following stem cell transplantation.

2. Ophthalmology

Akari is also exploring the use of nomacopan in ophthalmic indications, such as:

  • Dry Age-Related Macular Degeneration (Dry AMD): A leading cause of vision loss in older adults.
  • Uveitis: An inflammatory condition affecting the middle layer of the eye.

3. Other Therapeutic Areas

The company is investigating additional applications for its pipeline, including treatments for pulmonary and renal diseases. These efforts underscore Akari’s commitment to expanding its therapeutic reach.

Business Model

Akari Therapeutics employs a research-driven business model centered on the development and commercialization of novel therapies for rare diseases. The company’s approach includes:

  • Proprietary Technology: Akari leverages its proprietary platform to develop innovative treatments targeting complement and leukotriene pathways.
  • Clinical Development: The company invests heavily in clinical trials to validate the safety and efficacy of its product candidates.
  • Partnerships and Collaborations: Akari collaborates with academic institutions, research organizations, and industry partners to accelerate drug development and expand its market reach.
  • Revenue Generation: While Akari is currently in the development stage and does not yet generate significant revenue, the company aims to commercialize its therapies upon regulatory approval.

Strategic Direction

Akari Therapeutics is focused on advancing its pipeline of therapeutic candidates and achieving key milestones in clinical development. The company’s strategic priorities include:

  • Regulatory Approvals: Securing regulatory approvals for nomacopan in multiple indications.
  • Pipeline Expansion: Exploring additional therapeutic applications for its platform technology.
  • Global Market Penetration: Establishing a strong presence in key markets, including North America, Europe, and Asia.
  • Sustainability Goals: Incorporating sustainable practices into its operations and supply chain.
  • Innovation: Investing in research and development to maintain a competitive edge in the biopharmaceutical industry.

Competitive Landscape

Akari Therapeutics operates in a highly competitive market, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Alexion Pharmaceuticals (AstraZeneca): A leader in complement inhibition therapies, particularly for PNH and other rare diseases.
  • Apellis Pharmaceuticals: Known for its focus on complement-mediated diseases.
  • Regeneron Pharmaceuticals: A major player in ophthalmology and inflammatory disease treatments.
  • Smaller Biotech Firms: Companies developing niche therapies for rare and orphan diseases.

Akari differentiates itself through its dual-action mechanism of nomacopan and its focus on underserved patient populations.

Risk Factors

Like any biopharmaceutical company, Akari Therapeutics faces several risks, including:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals could impact the company’s ability to commercialize its therapies.
  • Market Dependence: The company’s reliance on a single product candidate, nomacopan, poses a significant risk.
  • Supply Chain Disruptions: Challenges in sourcing raw materials or manufacturing could delay product development.
  • Competition: Intense competition from larger, well-funded companies could limit Akari’s market share.
  • Financial Risks: As a development-stage company, Akari depends on external funding to sustain its operations.

Recent Developments

Akari Therapeutics has made significant progress in advancing its pipeline. Recent developments include:

  • Clinical Trials: The company has initiated Phase III trials for nomacopan in BP and HSCT-TMA, demonstrating its commitment to addressing unmet medical needs.
  • Collaborations: Akari has entered into partnerships with leading research institutions to explore new therapeutic applications for its platform.
  • Regulatory Milestones: The company has received orphan drug designations for nomacopan in multiple indications, highlighting its potential to address rare diseases.
  • Global Developments: The COVID-19 pandemic has underscored the importance of resilient supply chains and accelerated the adoption of digital technologies in clinical trials.

Investment Considerations

Investors considering Akari Therapeutics should weigh the following factors:

Strengths

  • Innovative Pipeline: A robust pipeline targeting rare and orphan diseases.
  • Orphan Drug Designations: Regulatory incentives, including market exclusivity and tax benefits.
  • Experienced Leadership: A management team with a proven track record in drug development.

Risks

  • Development Stage: The company has yet to commercialize any products, making it a high-risk investment.
  • Regulatory Uncertainty: Potential delays or failures in clinical trials and approvals.
  • Financial Dependence: Reliance on external funding to sustain operations.

Conclusion

Akari Therapeutics PLC is a promising biopharmaceutical company with a focus on developing innovative treatments for rare and orphan diseases. While the company faces significant risks, its proprietary platform, experienced leadership, and commitment to addressing unmet medical needs position it as a potential leader in the biopharmaceutical industry. With a strong pipeline and strategic focus, Akari is well-positioned for future growth, provided it can navigate the challenges inherent in drug development and commercialization.